Last reviewed · How we verify
99Mo — Competitive Intelligence Brief
unknown
Bone
Live · refreshed every 30 min
Target snapshot
99Mo (Molybdenum Mo-99). 99Mo is converted into Tc-99m through a nuclear reaction, which is then used to create diagnostic imaging agents.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 99Mo TARGET | Molybdenum Mo-99 | unknown |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). 99Mo — Competitive Intelligence Brief. https://druglandscape.com/ci/molybdenum-mo-99. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing